 ARC-000 is a new RNAi-based therapeutic in Arrowhead's HBV portfolio that was developed to target both cccDNA derived mRNA transcripts, like ARC-000, as well as those from HBV DNA that has integrated into the host DNA. It is intended to address specific patient populations that are predicted to have higher ratios of integrated DNA versus cccDNA. The Company plans to begin clinical studies of ARC-000 in mid-0000. 